NASDAQ$VANI
Vivani Medical, Inc · Q4 2026 earnings
Q4 2026 earnings · · Before market open
Briefing
Vivani Medical reported fiscal Q4 2026 revenue of $0 with a net loss of $6.8M and diluted loss per share of $0.08.
For the quarter ended March 31, 2026, Vivani Medical had no product revenue and reported a net loss of $6.8 million versus $8.2 million a year ago. Diluted loss per share was $0.08 compared with $0.11. R&D expense was $5.4 million as the company advanced miniaturized GLP-1 implant programs. G&A was $2.8 million with modest interest income partially offsetting operating losses.
- No revenue; net loss narrowed to $6.8M from $8.2M.
- Diluted loss per share improved to $0.08 from $0.11.
- R&D spend of $5.4M on implantable metabolic drug delivery.
- Pre-commercial stage with clinical milestones ahead.
- Cash runway discussed in MD&A for continued development.
Headline financials
Revenue & EPS history
Vivani Medical, Inc · Revenue · Quarterly
$0
Forward guidance
Vivani does not provide quantitative financial guidance in the 10-Q and outlines clinical development timelines for its NanoPortal implant platform.
Tailwinds
- Net loss and loss per share improved year over year.
- Focused R&D on GLP-1 implant candidates continues.
Headwinds
- No commercial revenue and ongoing clinical development burn.
- Regulatory and trial timelines remain uncertain.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2026
+0.6%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+1.5%
Avg return
30 days after
52%
13 / 25 earnings
Positive
+27.6%
Q1 2021
Best reaction
-11.4%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.8% | -0.9% | -3.5% | |
| Q3 2025 | -11.4% | -7.8% | -11.8% | |
| Q2 2025 | -0.8% | -2.4% | -4.7% | |
| Q1 2025 | +1.9% | +0.0% | +15.5% | |
| Q3 2024 | +11.2% | +5.6% | +4.8% | |
| Q2 2024 | +0.0% | +10.3% | +6.9% | |
| Q4 2022 | +2.1% | -8.4% | +13.4% | |
| Q1 2022 | +0.7% | +36.1% | +45.6% | |
| Q3 2021 | +1.5% | -3.7% | -28.7% | |
| Q2 2021 | -5.0% | -9.7% | -6.3% | |
| Q1 2021 | +27.6% | -1.2% | +33.0% | |
| Q3 2020 | +1.3% | +4.6% | +78.5% | |
| Q2 2020 | +3.4% | +17.8% | -14.8% | |
| Q1 2020 | -4.0% | -1.0% | -11.0% | |
| Q3 2019 | -5.3% | -8.5% | -15.5% | |
| Q2 2019 | +0.4% | +7.6% | +4.9% | |
| Q1 2019 | -7.5% | -17.6% | -31.9% | |
| Q3 2018 | -4.7% | -14.1% | -37.6% | |
| Q2 2018 | +1.8% | -1.8% | +6.7% | |
| Q1 2018 | +1.5% | +10.8% | -8.2% | |
| Q3 2017 | +0.0% | +3.5% | +31.3% | |
| Q2 2017 | -6.6% | -20.3% | -7.4% | |
| Q1 2017 | +0.0% | -0.9% | -2.6% | |
| Q3 2016 | -1.5% | -4.5% | -4.5% | |
| Q2 2016 | +5.3% | -3.0% | -15.7% | |
| Q1 2016 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro